These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8589296)

  • 21. Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
    Lee CT; Liao SC; Hsu KT; Lam KK; Chen JB
    Ren Fail; 1999 Nov; 21(6):665-73. PubMed ID: 10586429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity.
    Yokel RA; Meurer KA; Hong CB; Dickey KM; Skinner TL; Fredenburg AM
    Drug Metab Dispos; 1997 Feb; 25(2):182-90. PubMed ID: 9029049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low percentage of aluminoxamine and ferrioxamine in uremic serum after desferrioxamine administration.
    Menéndez-Fraga P; Fernández-Martín JL; Blanco-González E; Cannata-Andía JB
    Clin Chem; 1998 Jun; 44(6 Pt 1):1262-8. PubMed ID: 9625051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
    D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME
    Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intestinal mucormycosis in a hemodialysis patient treated with desferrioxamine.
    Kaneko T; Abe F; Ito M; Hotchi M; Yamada K; Okada Y
    Acta Pathol Jpn; 1991 Jul; 41(7):561-6. PubMed ID: 1755321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of chelating agents in the treatment of aluminum overload.
    Domingo JL
    J Toxicol Clin Toxicol; 1989; 27(6):355-67. PubMed ID: 2697761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine.
    Coburn JW; Norris KC
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):12-21. PubMed ID: 3299588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Removal of aluminum during hemodialysis: effect of different dialyzer membranes.
    Muirhead N; Hollomby DJ; Leung FY; Mitton R; Henderson AR; Keown PA; Stiller CR
    Am J Kidney Dis; 1986 Jul; 8(1):51-5. PubMed ID: 3728462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Red blood cell aluminum in patients with renal failure and effect of desferrioxamine infusion.
    Umeda M; Tsurusaki K; Kamikawa S; Izumi N; Yasumoto R; Kishimoto T; Maekawa M
    Blood Purif; 1990; 8(5):295-300. PubMed ID: 2091689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: role of aluminum toxicity.
    Tarng DC; Huang TP
    Am J Nephrol; 1998; 18(1):1-8. PubMed ID: 9481432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Removal of aluminum from chronic dialysis patients by administration of desferrioxamine and dialysis.
    Ono T; Iwamoto N; Kataoka H; Taniguchi Y; Sakai Y; Kunitomo T
    ASAIO Trans; 1986; 32(1):52-7. PubMed ID: 3778761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
    Sherrard DJ; Walker JV; Boykin JL
    Am J Kidney Dis; 1988 Aug; 12(2):126-30. PubMed ID: 3400633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deferoxamine for aluminum toxicity in dialysis patients.
    Hernandez P; Johnson CA
    ANNA J; 1990 Jun; 17(3):224-8. PubMed ID: 2357118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose desferrioxamine test for the diagnosis of aluminium-related bone disease in patients on regular haemodialysis.
    Yaqoob M; Ahmad R; Roberts N; Helliwell T
    Nephrol Dial Transplant; 1991; 6(7):484-6. PubMed ID: 1922909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Failure of deferoxamine to improve iron overload in chronic hemodialysis patients.
    Roxe DM; Krumlovsky FA; Del Greco F; Fitzsimons E
    Int J Artif Organs; 1990 Apr; 13(4):211-7. PubMed ID: 2115505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature.
    Boelaert JR; van Roost GF; Vergauwe PL; Verbanck JJ; de Vroey C; Segaert MF
    Clin Nephrol; 1988 May; 29(5):261-6. PubMed ID: 3293856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease.
    Felsenfeld AJ; Rodriguez M; Coleman M; Ross D; Llach F
    Kidney Int; 1989 Jun; 35(6):1371-8. PubMed ID: 2770115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of aluminium intoxication: a new scheme for desferrioxamine administration.
    Douthat WG; Acuña Aguerre G; Fernández Martín JL; Mouzo R; Cannata Andía JB
    Nephrol Dial Transplant; 1994; 9(10):1431-4. PubMed ID: 7816256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion.
    Poignet JL; Monge MF; Ciancioni C; Mikol F; Naret C; Delons S; Man NK
    Trans Am Soc Artif Intern Organs; 1985; 31():546-51. PubMed ID: 3837504
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.